%0 Journal Article
%T Comments on the trial of cisplatin and etoposide plus thoracic radiotherapy followed by nivolumab or placebo for locally advanced non-small cell lung cancer (RTOG 3505)
%A Dae Ho Lee
%A Sang-We Kim
%A Shinkyo Yoon
%J SCIE-indexed Journal
%D 2017
%R 10.21037/jtd.2017.09.12
%X Radiotherapy (RT) induce lethal DNA damage to tumor cells and the concurrent chemoradiation (CCRT) is the standard treatment option for inoperable stage III non-small cell lung cancer (NSCLC) until now (1). The expectancy of 5-year survival, however, is less than 20¨C25%. Thus, some modification or addition of new treatment modality would be a reasonable approach to improve its cure rate
%U http://jtd.amegroups.com/article/view/16252/html